{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Glumetinib",
  "nciThesaurus": {
    "casRegistry": "1642581-63-2",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, glumetinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",
    "fdaUniiCode": "7JTT036WGX",
    "identifier": "C156700",
    "preferredName": "Glumetinib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C143099"
    ],
    "synonyms": [
      "GLUMETINIB",
      "Glumetinib",
      "SCC 244",
      "SCC-244",
      "SCC244"
    ]
  }
}